utoantibodi
cytokin
frequent
report
healthi
individu
patient
autoimmun
infecti
diseas
sever
instanc
pathogen
role
cytokin
autoantibodi
formal
demonstr
case
autoantibodi
interleukin
il
patient
mucocutan
candidiasi
autoantibodi
interferon
ifn
g
patient
mycobacteri
infect
instanc
autoantibodi
shown
caus
sever
patholog
neutral
biolog
activ
target
cytokin
case
autoantibodi
granulocytemacrophag
colonystimul
factor
gmcsf
autoimmun
pulmonari
alveolar
proteinosi
pap
autoantibodi
erythropoietin
pure
redcel
aplasia
case
autoantibodi
product
link
administr
recombin
cytokin
erythropoietin
gmcsf
case
stimuli
elicit
product
cytokin
autoantibodi
remain
unknown
reason
cytokin
autoantibodi
may
may
caus
patholog
entir
clear
prevail
view
enough
affin
present
certain
threshold
concentr
autoantibodi
neutral
biolog
activ
cytokin
simpli
bind
prevent
interact
cognat
cellular
receptor
mechan
recapitul
vitro
use
cell
prolifer
bioassay
cytokinedepend
cell
line
interestingli
howev
sever
studi
toxin
cytokin
demonstr
synergi
differ
antibodi
bind
molecul
suggest
case
neutral
may
depend
product
antibodi
target
multipl
antigen
site
thu
lead
format
immun
complex
cytokin
effici
clear
vivo
addit
report
monoclon
antibodi
neutral
cytokin
activ
vitro
paradox
enhanc
extend
activ
inject
vivo
autoimmun
pap
rare
sever
diseas
caus
product
autoantibodi
neutral
biolog
activ
gmcsf
gmcsf
essenti
termin
differenti
function
alveolar
macrophag
respons
catabol
surfact
lipid
protein
lung
dysfunct
alveolar
macrophag
consequ
gmcsf
neutral
lead
accumul
lipoproteinac
materi
within
alveoli
caus
respiratori
insuffici
increas
risk
infect
addit
gmcsf
defici
result
impair
antimicrobi
activ
neutrophil
pathogen
role
gmcsf
autoantibodi
demonstr
adopt
transfer
gmcsf
autoantibodi
purifi
pap
patient
nonhuman
primat
sera
pap
patient
contain
level
autoantibodi
exceed
pathogen
threshold
mg
ml
bind
neutral
gmcsf
high
titr
recent
studi
report
isol
sever
monoclon
autoantibodi
pap
patient
show
differ
bind
affin
suggest
singl
human
monoclon
antibodi
neutral
cytokin
activ
block
bind
gmcsf
receptor
studi
isol
panel
monoclon
autoantibodi
pap
patient
show
singl
antibodi
partial
neutral
gmcsf
activ
vitro
depend
experiment
condit
bioassay
wherea
three
noncrosscompet
antibodi
complet
neutral
gmcsf
activ
addit
show
vivo
singl
antibodi
enhanc
level
bioavail
gmcsf
three
noncrosscompet
antibodi
induc
rapid
fcdepend
clearanc
cytokin
final
show
case
somat
mutat
critic
bind
gmcsf
suggest
clone
give
rise
autoantibodi
deriv
memori
rather
naiv
b
cell
character
gmcsf
autoantibodi
pap
patient
peripher
blood
mononuclear
cell
pbmc
sera
collect
five
chronic
pap
patient
age
rang
year
patient
high
serum
titr
gmcsf
autoantibodi
rang
mg
ml
supplementari
tabl
memori
b
cell
isol
immort
epsteinbarr
viru
cpg
describ
supernat
screen
presenc
gmcsfspecif
igg
use
enzymelink
immunosorb
assay
elisa
clone
produc
gmcsf
autoantibodi
monoclon
antibodi
mab
identifi
antibodi
v
gene
sequenc
analys
use
imgt
intern
immunogenet
inform
system
databas
antibodi
use
k
light
chain
clear
prefer
v
gene
usag
load
somat
mutat
compar
characterist
tcelldepend
respons
nonselfantigen
rang
vh
gene
segment
vl
gene
segment
antibodi
produc
recombinantli
test
bind
gmcsf
tabl
valu
determin
use
elisa
rang
ng
ml
k
valu
determin
surfac
plasmon
reson
spr
rang
nm
consist
highaffin
bind
notic
kinet
valu
heterogen
instanc
antibodi
compar
k
valu
show
differ
kinet
character
low
onlow
offrat
high
onhigh
offrat
properti
monoclon
antibodi
isol
consist
polyclon
respons
somat
mutat
b
cell
bind
gmcsf
depend
somat
mutat
role
somat
mutat
develop
gmcsf
autoantibodi
investig
test
version
autoantibodi
somat
mutat
whole
v
j
gene
remov
refer
antibodi
variant
unmut
common
ancestor
uca
also
produc
shuffl
variant
vh
vl
revert
uca
sequenc
analys
use
spr
elisa
five
seven
uca
antibodi
test
bind
gmcsf
remain
two
show
reduc
still
detect
bind
fig
supplementari
tabl
shuffl
experi
show
somat
mutat
heavi
chain
play
major
role
highaffin
bind
sinc
precis
identif
somat
mutat
possibl
due
difficulti
unequivoc
assign
segment
determin
junction
rearrang
also
test
antibodi
variant
v
gene
segment
revert
germlin
sequenc
left
wildtyp
form
interestingli
four
seven
case
remov
mutat
v
segment
suffici
abolish
bind
supplementari
tabl
provid
formal
evid
role
somat
mutat
determin
autoantibodi
specif
gmcsf
autoantibodi
form
highmolecularweight
complex
use
spr
crosscompetit
experi
identifi
multipl
antigen
site
gmcsf
complet
antigen
map
base
matrix
crosscompetit
experi
gener
fig
site
ii
iii
iv
defin
four
noncrosscompet
autoantibodi
interestingli
use
spr
could
show
three
noncrosscompet
autoantibodi
bind
simultan
singl
molecul
gmcsf
fig
furthermor
gmcsf
incub
excess
three
antibodi
format
highmolecularweight
immun
complex
could
detect
use
sizeexclus
chromatographyhighperform
liquid
chromatographi
sechplc
fig
complet
vitro
neutral
gmcsf
three
antibodi
neutral
activ
autoantibodi
assess
measur
abil
inhibit
prolifer
cell
respons
recombin
gmcsf
polyclon
igg
autoantibodi
purifi
sera
pap
patient
show
potent
complet
neutral
activ
valu
rang
mg
ml
mg
ml
respect
fig
valu
estim
gmcsf
autoantibodi
account
total
igg
serum
pap
patient
mg
ml
find
consist
previou
report
indic
pap
patient
high
level
gmcsf
autoantibodi
capabl
neutral
biolog
activ
cytokin
surprisingli
bioassay
monoclon
autoantibodi
fail
neutral
gmcsf
fig
except
neutral
gmcsf
activ
valu
mg
ml
therapeut
antibodi
namilumab
ref
show
valu
respect
interestingli
combin
togeth
two
noncrosscompet
antibodi
show
enhanc
neutral
activ
term
doserespons
percent
inhibit
combin
site
site
iv
effect
fig
furthermor
combin
three
noncrosscompet
antibodi
specif
site
ii
iv
led
complet
inhibit
prolifer
valu
mg
ml
express
total
concentr
three
mab
lower
therapeut
antibodi
namilumab
strong
synergi
three
noncrosscompet
antibodi
observ
combin
test
valu
compar
affinitypurifi
antibodi
pap
sera
supplementari
fig
consid
law
mass
action
hypothes
presenc
singl
antibodi
small
fraction
gmcsf
may
continu
dissoci
antibodi
becom
avail
trigger
highaffin
gmcsf
receptor
contrast
presenc
three
antibodi
gmcsf
may
sequest
irrevers
stabl
immun
complex
expect
law
mass
action
found
vari
cell
number
gmcsf
concentr
sensit
assay
dramat
affect
particular
lower
number
cell
concentr
gmcsf
led
sensit
test
show
increas
neutral
singl
multipl
antibodi
fig
contrast
high
number
cell
high
dose
gmcsf
use
even
potent
neutral
antibodi
namilumab
fail
neutral
gmcsf
even
present
molar
excess
strikingli
condit
combin
three
noncrosscompet
antibodi
capabl
complet
neutral
gmcsf
establish
gmcsf
form
complex
three
antibodi
result
effici
vitro
neutral
cytokin
biolog
activ
interest
understand
effect
singl
versu
multipl
autoantibodi
vivo
mice
inject
total
mg
singl
multipl
monoclon
antibodi
mg
igg
fraction
isol
serum
pap
patient
follow
inject
mg
human
gmcsf
differ
time
point
serum
collect
amount
gmcsf
present
measur
sandwich
elisa
use
antibodi
specif
site
ii
captur
site
detect
assay
perform
serum
either
untreat
alkalin
treatment
dissoci
immun
complex
supplementari
fig
absenc
antibodi
inject
gmcsf
disappear
rapidli
serum
undetect
h
fig
contrast
singl
antibodi
use
high
level
gmcsf
recov
serum
day
still
present
day
note
gmcsf
detect
requir
alkalin
dissoci
case
consist
differ
dissoci
rate
two
antibodi
tabl
strike
contrast
mice
receiv
three
noncrosscompet
antibodi
pap
igg
gmcsf
rapidli
clear
sinc
low
undetect
amount
cytokin
could
detect
sera
respect
alkalin
dissoci
address
possibl
role
fc
receptor
clearanc
gmcsf
test
antibodi
variant
form
call
lala
bind
fcg
receptor
similarli
wildtyp
antibodi
singl
lala
antibodi
led
increas
gmcsf
level
serum
howev
contrast
observ
three
wildtyp
antibodi
three
lala
antibodi
fail
clear
gmcsf
quantit
recov
sera
follow
alkalin
dissoci
even
day
fig
ask
whether
antibodybound
gmcsf
would
bioavail
test
sera
mice
abil
support
prolifer
fig
sera
mice
receiv
led
robust
prolifer
cell
consist
gmcsf
dissoci
rate
suffici
engag
cytokin
receptor
contrast
sera
mice
receiv
three
wildtyp
antibodi
pap
igg
abl
stimul
prolifer
consist
clearanc
immun
complex
vivo
addit
although
contain
high
level
gmcsf
sera
mice
receiv
three
lala
antibodi
stimulatori
find
consist
irrevers
sequestr
gmcsf
stabl
immun
complex
address
role
fcg
receptor
test
immun
complex
form
gmcsf
wildtyp
lala
antibodi
capac
bind
tzmbl
cell
express
differ
fcg
receptor
strong
bind
observ
fcgriiaand
fcgriibexpress
cell
immun
complex
form
three
wildtyp
lala
antibodi
fig
supplementari
fig
taken
togeth
result
indic
singl
antibodi
even
potent
neutral
vitro
increas
halflif
gmcsf
build
circul
pool
bioavail
cytokin
contrast
three
antibodi
lead
format
immun
complex
effici
clear
fcdepend
mechan
low
level
gmcsf
autoantibodi
healthi
donor
address
whether
low
level
autoantibodi
gmcsf
may
found
serum
healthi
donor
took
advantag
synergi
autoantibodi
gmcsf
neutral
test
capac
neutral
gmcsf
bioactiv
cell
igg
fraction
isol
serum
healthi
donor
show
detect
neutral
activ
howev
serum
igg
supplement
singl
nonneutr
monoclon
antibodi
clear
neutral
activ
measur
vari
depend
serum
donor
site
specif
antibodi
use
one
case
could
observ
complet
neutral
use
serum
igg
donor
combin
antibodi
fig
result
suggest
low
level
antigmcsf
antibodi
devoid
neutral
activ
present
sera
healthi
donor
detect
use
sensit
complement
assay
studi
identifi
two
mechan
polyclon
antigmcsf
antibodi
produc
pap
patient
inhibit
biolog
activ
gmcsf
first
irrevers
sequestr
gmcsf
highmolecularweight
immun
complex
readili
detect
vitro
use
cell
prolifer
bioassay
second
vivo
fcdepend
degrad
immun
complex
form
gmcsf
multipl
autoantibodi
autoantibodi
isol
show
affin
nanomolar
rang
distinct
kinet
bind
differ
particular
offrat
overal
compar
report
recent
studi
interestingli
studi
claim
antibodi
capabl
neutral
gmcsf
bioassay
show
neutral
singl
antibodi
strictli
depend
concentr
cytokin
number
receptor
system
find
explain
revers
antibodyantigen
interact
accord
law
mass
action
affin
gmcsf
receptor
ligand
higher
antibodi
therefor
interest
discov
ad
togeth
three
antibodi
bind
nonoverlap
site
complet
articl
neutral
gmcsf
bioactiv
irrespect
concentr
cytokin
receptor
test
stringent
condit
cocktail
three
antibodi
weight
basi
potent
two
antigmcsf
antibodi
current
develop
therapi
autoimmun
inflammatori
diseas
envisag
complex
three
antibodi
gmcsf
becom
complet
sequest
longer
avail
interact
receptor
key
observ
studi
inject
mice
singl
antibodi
led
accumul
larg
pool
longliv
gmcsf
still
abl
dissoci
trigger
receptor
shown
capac
sera
stimul
prolifer
cell
capac
singl
antibodi
build
larg
cytokin
reservoir
observ
gmcsf
could
basi
enhanc
activ
monoclon
antibodi
common
gammachain
cytokin
vivo
strike
contrast
show
three
antibodi
form
immun
complex
rapidli
degrad
vivo
fcdepend
manner
degrad
gmcsf
induc
polyclon
antibodi
reminisc
previou
studi
three
antibodi
shown
caus
degrad
vivo
result
extend
concept
autoantibodi
suggest
degrad
main
mechan
polyclon
autoantibodi
found
serum
pap
patient
lead
complet
clearanc
cytokin
thu
explain
sever
phenotyp
characterist
patient
summari
result
suggest
twostep
mechan
polyclon
antibodi
lead
sever
gmcsf
defici
first
irrevers
sequest
gmcsf
thu
complet
prevent
interact
receptor
second
induc
degrad
fcdepend
manner
find
also
help
explain
pap
report
follow
administr
antigmcsf
monoclon
antibodi
human
suggest
main
effect
therapeut
antigmcsf
antibodi
would
redistribut
cytokin
circul
thu
decreas
concentr
inflammatori
site
leav
enough
free
gmcsf
develop
alveolar
macrophag
addit
worth
consid
system
administ
igg
accumul
preferenti
inflam
tissu
compar
lung
interest
observ
studi
relat
role
somat
mutat
presenc
low
level
gmcsf
antibodi
healthi
individu
find
uca
autoantibodi
bind
show
minim
bind
gmcsf
consist
previou
studi
role
somat
mutat
determin
specif
autoantibodi
desmoglein
dna
patient
pemphigu
lupu
contrast
observ
uca
version
antivir
antibodi
show
slightli
reduc
bind
specif
antigen
find
support
notion
autoantibodi
preferenti
gener
activ
memori
b
cell
trigger
undergon
somat
mutat
respons
foreign
antigen
tempt
specul
preferenti
origin
autoantibodi
memori
b
cell
fact
cell
lower
activ
threshold
may
difficult
anerg
compar
naiv
b
cell
addit
suggest
memori
b
cell
may
abl
effici
prime
naiv
cell
gmcsf
autoantibodi
describ
pap
patient
also
serum
healthi
donor
patient
inflammatori
bowel
diseas
normal
pulmonari
function
build
find
develop
sensit
complement
assay
detect
serum
healthi
donor
nonneutr
gmcsf
autoantibodi
base
capac
synerg
nonneutr
monoclon
autoantibodi
find
suggest
healthi
donor
may
antigmcsf
antibodi
serum
low
concentr
andor
combin
promot
gmcsf
sequestr
degrad
convers
pap
patient
develop
high
level
gmcsf
autoantibodi
multipl
site
form
immun
complex
mediat
sequestr
degrad
cytokin
isol
product
monoclon
antibodi
pap
patient
peripher
blood
sampl
obtain
five
pap
patient
high
level
gmcsf
autoantibodi
determin
serum
level
gmcsf
autoantibodi
perform
laboratori
rare
lung
diseas
consortium
cincinnati
children
hospit
medic
center
describ
briefli
elisa
plate
maxisorp
nunc
coat
mg
ml
recombin
human
gmcsf
miltenyi
biotec
block
block
solut
stabilcoat
surmod
eden
prairi
mn
usa
incub
titrat
sera
follow
incub
horseradish
peroxidaseconjug
antihuman
igg
f
ab
fragment
plate
wash
substrat
tetramethylbenzidin
sigmaaldrich
ad
follow
n
h
plate
read
nm
serum
concentr
gmcsf
autoantibodi
determin
gmcsfautoantibodi
polyclon
refer
standard
quadrat
regress
analysi
use
microsoft
excel
microsoft
corp
seattl
wa
usa
diseas
sever
score
combin
presenc
articl
absenc
symptom
degre
determin
accord
classif
previous
describ
memori
b
cell
isol
cryopreserv
fresh
pbmc
use
antifluorescein
isothiocyan
fitc
microbead
miltenyi
biotec
follow
stain
pbmc
bd
phamingen
immort
epsteinbarr
viru
cpg
multipl
well
describ
previous
cultur
supernat
test
bind
recombin
human
gmcsf
gentaur
use
elisa
cdna
synthes
posit
cultur
heavi
chain
light
chain
variabl
region
sequenc
monoclon
antibodi
produc
recombinantli
transient
transfect
hek
freestyl
cell
invitrogen
use
polyethylenimin
test
bind
gmcsf
use
elisa
studi
conduct
accord
declar
helsinki
guidelin
approv
ethic
committe
ircc
san
matteo
hospit
foundat
pavia
itali
patient
gave
inform
consent
sequenc
analysi
antibodi
revers
germlin
usag
vh
vl
gene
amount
somat
mutat
determin
analys
homolog
vh
vl
sequenc
mab
known
human
v
j
gene
imgt
databas
sequenc
uca
determin
revert
mutat
germlin
sequenc
retain
origin
junction
termin
deoxynucleotidyl
transferas
n
nucleotid
uca
sequenc
put
mutat
remov
also
determin
vh
uca
vh
uca
wt
vl
uca
nucleotid
sequenc
synthes
genscript
accuraci
confirm
sequenc
four
differ
version
seven
select
mab
produc
recombinantli
uca
wt
shuffl
mab
either
vh
uca
wildtyp
vl
wildtyp
vh
vl
uca
antibodi
purif
elisa
assay
human
mab
total
igg
pap
sera
purifi
protein
protein
g
chromatographi
ge
healthcar
total
igg
healthi
donor
purifi
use
hitrap
protein
hp
column
ge
healthcar
concentr
use
amicon
ultra
filter
unit
k
millipor
total
gmcsf
antibodi
affinitypurifi
pap
sera
use
magnet
bead
invitrogen
conjug
human
gmcsf
total
igg
quantifi
use
elisa
plate
coat
antihuman
igg
southernbiotech
use
certifi
refer
materi
sigmaaldrich
standard
bind
gmcsf
test
elisa
use
spectrapl
perkinelm
primari
screen
maxisorp
plate
nunc
follow
test
briefli
elisa
plate
coat
mg
ml
recombin
human
gmcsf
gentaur
block
bsa
incub
titrat
antibodi
follow
apconjug
antihuman
igg
secondari
antibodi
southernbiotech
plate
wash
substrat
pnpp
sigma
ad
plate
read
nm
ng
ml
calcul
everi
sampl
nonlinear
regress
analysi
use
graphpad
prism
softwar
sizeexclus
hplc
three
noncrosscompet
mab
dilut
pb
singularli
threeantibodycombin
mg
total
antibodi
amount
mix
gmcsf
molar
ratio
h
room
temperatur
rt
sampl
analys
agil
hplc
machin
use
tskgel
column
tosoh
bed
volum
ml
void
volum
ml
pb
mobil
phase
flow
rate
ml
min
univers
solvent
filter
agil
put
injector
column
detect
perform
use
variabl
wavelength
detector
agil
ultraviolet
absorpt
nm
prolifer
bioassay
cell
cell
line
servic
maintain
rpmi
medium
supplement
fetal
bovin
serum
hyclon
glutamax
penicillinstreptavidin
nonessenti
amino
acid
sodium
pyruv
gibco
ng
ml
human
gmcsf
gentaur
ng
ml
human
immunotool
cell
grown
humidifi
incub
co
gmcsf
neutral
assay
perform
serial
dilut
mab
combin
mab
total
igg
affinitypurifi
antibodi
growth
medium
neither
gmcsf
ad
gmcsf
concentr
pg
ml
preincub
flatbottom
cell
cultur
plate
costar
h
cell
wash
five
time
dilut
growth
medium
neither
gmcsf
cell
per
well
seed
final
gmcsf
concentr
equal
pg
ml
test
gmcsf
use
final
concentr
pg
ml
cell
per
well
seed
cell
without
gmcsf
absenc
antibodi
use
control
determin
maximum
minimum
level
cell
prolifer
plate
incub
humidifi
incub
co
h
cell
prolifer
measur
incub
mci
per
well
thymidin
perkinelm
gmcsf
neutral
calcul
percentag
inhibit
growth
follow
formula
ccpm
singl
well
averag
ccpm
control
cell
grown
without
gmcsf
averag
ccpm
control
cell
grown
gmcsf
averag
ccpm
control
cell
grown
without
gmcsf
ccpm
correct
count
per
minut
mg
ml
calcul
everi
sampl
nonlinear
regress
analysi
use
graphpad
prism
softwar
experi
mous
sera
titrat
growth
medium
preincub
min
cell
wash
seed
cell
per
well
titrat
gmcsf
ng
ml
ad
growth
control
ccpm
singl
well
plot
serum
titrat
vivo
clearanc
gmcsf
immun
complex
balbc
mice
suppli
jackson
laboratori
usa
harlan
itali
charl
river
germani
itali
anim
experi
approv
canton
autorithi
canton
ticino
group
femal
balbc
mice
inject
intraven
mg
purifi
mab
mg
total
igg
purifi
patient
h
mg
human
gmcsf
inject
serum
sampl
collect
day
day
gmcsf
quantifi
sandwich
elisa
briefli
mg
ml
antibodi
bound
site
ii
gmcsf
use
coat
maxisorp
plate
nunc
block
pb
fb
gibco
sera
gmcsf
use
standard
rang
pg
ml
titrat
test
parallel
differ
condit
one
plate
sampl
supplement
volvol
alkalin
dissoci
buffer
triton
ethanolamin
nacl
ph
plate
sampl
supplement
volvol
pb
fb
plate
left
overnight
rt
detect
captur
gmcsf
made
mg
ml
biotinyl
antibodi
bound
site
gmcsf
h
rt
follow
bind
mg
ml
streptavidinap
jackson
immunoresearch
h
rt
plate
wash
substrat
pnpp
sigma
ad
plate
read
nm
bind
gmcsf
immun
complex
fccr
four
tzmbl
cell
line
nih
aid
research
refer
reagent
program
transfect
specif
fcg
receptor
fcgri
fcgriia
fcgriib
fcgriiia
maintain
dmem
medium
supplement
fetal
bovin
serum
hyclon
hepe
mg
ml
gentamicin
mg
ml
blasticidin
untransfect
tzmbl
cell
use
neg
control
maintain
dmem
medium
supplement
fetal
bovin
serum
hyclon
penicillinstreptavidin
cell
grown
humidifi
incub
co
express
specif
fcgr
assess
stain
tzmbl
cell
fitcconjug
antifcgri
antifcgriia
antifcgriib
antifcgriiia
antibodi
bd
pharmingen
untransfect
transfect
tzmbl
cell
wash
stain
buffer
pb
fetal
bovin
serum
mm
edta
seed
plate
densiti
cell
per
well
singl
antigmcsf
mab
combin
three
noncrosscompet
mab
final
concentr
mg
ml
mix
mg
ml
gmcsf
stain
buffer
pb
fetal
bovin
serum
mm
edta
lala
version
antibodi
mab
differ
specif
includ
control
sampl
incub
min
allow
format
immun
complex
cool
ad
tzmbl
cell
min
cell
wash
twice
stain
antihuman
igg
fcg
fragment
specif
f
ab
fragment
jackson
immunoresearch
sampl
analys
bd
facscanto
bd
bioscienc
median
intens
fluoresc
analys
compar
sampl
